Tesaro $TSRO has come through with a development and marketing partner for Japan.
Not surprisingly, Takeda stepped in to grab Japanese rights for niraparib (Zejula), its recently approved PARP inhibitor. Takeda gets rights on all indications in Japan and all indications except prostate cancer in South Korea, Taiwan, Russia and Australia.
In exchange, Tesaro – often named as a likely though pricey takeover target – gets $100 million upfront and another $240 million in milestones.
Under CEO Christophe Weber, Takeda has been a busy dealmaker over the past year, looking to beef up its pipeline and expand in the oncology market. That strategy led to Takeda’s acquisition of Ariad early this year in a $5.2 billion buyout.
“We are pleased to be collaborating with Tesaro, a company we admire for its high caliber oncology expertise,” said Christophe Bianchi, president of Takeda Oncology. “This agreement represents another step in our goal of building Takeda’s robust portfolio in solid tumors and, more importantly, our commitment to patients living with cancer who desperately want – and need – new, innovative therapies.”
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription